Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
Lumos Pharma (NASDAQ:LUMO), a late-stage biopharmaceutical company focusing on rare disease therapeutics, has announced it will report its second quarter 2024 financial results after market close on August 1, 2024. The company will host a conference call and webcast at 4:30pm ET the same day to discuss these results and provide updates on clinical and corporate activities.
The call will include a question-and-answer session following prepared remarks. Participants can join via phone or webcast, with dial-in registration available 15 minutes before the scheduled start time. A replay of the call will be accessible through the company's website after the event.
Lumos Pharma (NASDAQ:LUMO), un'azienda biofarmaceutica in fase avanzata che si concentra sulle terapie per malattie rare, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 dopo la chiusura del mercato il 1 agosto 2024. L'azienda terrà una chiamata conferenza e un webcast alle 16:30 ET nello stesso giorno per discutere questi risultati e fornire aggiornamenti sulle attività cliniche e aziendali.
La chiamata includerà una sessione di domande e risposte dopo le osservazioni preparate. I partecipanti possono unirsi tramite telefono o webcast, con registrazione per la chiamata disponibile 15 minuti prima dell'orario di inizio programmato. Una registrazione della chiamata sarà accessibile tramite il sito web dell'azienda dopo l'evento.
Lumos Pharma (NASDAQ:LUMO), una empresa biofarmacéutica en etapa avanzada centrada en las terapias para enfermedades raras, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 después del cierre del mercado el 1 de agosto de 2024. La empresa llevará a cabo una llamada de conferencia y webcast a las 4:30 p.m. ET el mismo día para discutir estos resultados y proporcionar actualizaciones sobre las actividades clínicas y corporativas.
La llamada incluirá una sesión de preguntas y respuestas después de los comentarios preparados. Los participantes pueden unirse a través del teléfono o del webcast, con registro por teléfono disponible 15 minutos antes de la hora de inicio programada. Una grabación de la llamada estará accesible a través del sitio web de la empresa después del evento.
Lumos Pharma (NASDAQ:LUMO)는 희귀 질환 치료제에 주력하는 후반 단계의 생물 의약품 회사로, 2024년 2분기 재무 결과를 2024년 8월 1일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분(ET)에 전화 회의 및 웹캐스트를 개최하여 이 결과를 논의하고 임상 및 기업 활동에 대한 업데이트를 제공할 것입니다.
이 회의에는 준비된 발언 후 질의응답 세션이 포함됩니다. 참여자는 전화 또는 웹캐스트를 통해 참석할 수 있으며, 예정된 시작 시간 15분 전에 전화 등록이 가능합니다. 회의의 재생은 이벤트 후 회사 웹사이트를 통해 접근할 수 있습니다.
Lumos Pharma (NASDAQ:LUMO), une entreprise bio-pharmaceutique en phase avancée se concentrant sur les thérapeutiques pour les maladies rares, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 après la fermeture du marché le 1er août 2024. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET le même jour pour discuter de ces résultats et fournir des mises à jour sur les activités cliniques et corporatives.
La conférence inclura une session de questions-réponses après les remarques préparées. Les participants peuvent se joindre par téléphone ou par webinaire, avec une inscription par téléphone disponible 15 minutes avant l'heure de début prévue. Un enregistrement de la conférence sera accessible sur le site web de l'entreprise après l'événement.
Lumos Pharma (NASDAQ:LUMO), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf Therapeutika für seltene Erkrankungen konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 nach Börsenschluss am 1. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um diese Ergebnisse zu besprechen und Updates zu klinischen und unternehmensbezogenen Aktivitäten zu geben.
Die Konferenz wird eine Frage-und-Antwort-Runde nach den vorbereiteten Äußerungen beinhalten. Die Teilnehmer können per Telefon oder Webcast teilnehmen, wobei eine Anmeldung 15 Minuten vor dem geplanten Startzeitpunkt möglich ist. Eine Aufzeichnung der Konferenz wird nach der Veranstaltung über die Website des Unternehmens zugänglich sein.
- None.
- None.
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.
Conference Call and Webcast Details
Date: Thursday, August 1, 2024
Time: 4:30pm ET
Dial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)
Conference ID: 10191274
Dial-in registration (Available 15 minutes prior to scheduled start time): Click Here
Dial-in registration passcode: 2835283
Webcast: Click Here
Investors and the general public are invited to listen to the conference call. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast link may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay will be available after the date of the call and may be accessed through the same link above or found on our website.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
When will Lumos Pharma (LUMO) report its Q2 2024 financial results?
What time is Lumos Pharma's (LUMO) Q2 2024 earnings call scheduled for?
How can investors access Lumos Pharma's (LUMO) Q2 2024 earnings call?
Will there be a replay available for Lumos Pharma's (LUMO) Q2 2024 earnings call?
